Epithalon vs MOTS-c
Epithalon has telomere findings in cultured cells; MOTS-c has human endogenous-peptide observations and a native Phase 2 trial registration without cited outcomes. Neither has demonstrated human longevity benefit.
Last updated: September 28, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Epithalon
Dossier overview
MOTS-c
Dossier overview
Distinct research questions
Epithalon (epitalon, AEDG) is a synthetic tetrapeptide, distinct from pineal extracts. MOTS-c is encoded in the mitochondrial 12S rRNA region. Telomere and AMPK findings are laboratory or animal mechanisms, not interchangeable anti-aging effects in people. Epithalon cell study, PMID 12937682 · MOTS-c discovery/mouse study, PMID 25738459 · human exercise and mouse intervention, PMID 33473109 · native-peptide trial registration, NCT07505745
| Question | Epithalon | MOTS-c |
|---|---|---|
| Direct evidence | Telomere-related changes in cultured human cells, including a 2025 independent report | Mouse intervention experiments plus four selected human observational/physiology papers |
| Human administered-peptide result cited? | None | None; a native Phase 2 trial is registered without an outcome in this review |
| Therapeutic-claim grade | Low for human longevity | Low for human metabolic or longevity benefit |
The 2003 Epithalon study reported telomerase activity in cultured human fetal fibroblasts. A 2025 independent study reported telomere-related changes in cultured cells, including alternative-lengthening activity in breast-cancer lines; a published correction replaced figures. Neither establishes human healthspan, cancer risk or safety after administration. PMID 12937682 · PMID 40908429 · published correction
MOTS-c administration affected glucose-related measures in mice. Human sleep-apnea, diabetes and exercise papers measured the body’s own peptide rather than giving it as treatment. A 2026 physiology study did not detect an exercise-related human arterio-venous MOTS-c difference, even though it reported a muscle interstitial signal. PMID 40538389 · PMID 40855115 · PMID 41520850
NCT07505745 registers native MOTS-c for an insulin-sensitivity question in adults with prediabetes and overweight or obesity; no efficacy or safety result was cited in the accepted review. The completed CB4211 record concerns a distinct analog. A kidney-transplant anesthesia study measures MOTS-c but does not administer it. NCT07678073
A 2026 C26 mouse and cultured-cell study reported partial preservation of skeletal muscle with preventive MOTS-c exposure, without preventing overall body or fat loss; it did not treat established human cachexia. PMID 42266945
Neither peptide has an FDA-approved medicine verified here. FDA’s compounded-product safety discussion is route and substance specific; endogenous MOTS-c measurements do not establish administration safety. FDA compounding safety review
This is a selected-source comparison, not a longevity or treatment recommendation.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.